JSPR (Jasper Therapeutics) קצב צמיחת רווח למניה בשנה הנוכחית

The absence of current profitable assets makes Jasper Therapeutics (JSPR) dependent on R&D, which is why the relative annual EPS change on GURU.Markets reflects market expectations, where the value of 88.60 captures this status. The business potential is based on partnerships with transplant centers to improve cell engraftment, while management focuses on minimizing the toxicity of patient conditioning procedures.

Jasper Therapeutics develops vital drugs for stem cell transplantation that possess absolute macroeconomic resilience. The year-over-year earnings per share (EPS) dynamics quantify the efficiency of this non-cyclical business model. This metric measures the percentage deviation of current EPS from the same period last year, revealing the growth rates of capitalization. Daily monitoring allows for the prompt identification of trend reversals prior to the publication of financial reports. By analyzing the history of annual net income per share growth, an investor determines the phases of the company's financial cycle.